In April 2018, Tango Biosciences received a R41 award from NIH. The goals of the grant are to generate two-site capable affinity reagents through MegaSTAR to two sets of targets. One set represents biomarkers of colorectal cancer and myocardial infarction. MegaSTAR reagents will be benchmarked against existing commercial sandwich reagents, and the performance metrics (i.e., intra-assay and inter-assay precision, linearity, sensitivity) will be evaluated and compared through ELISA. The second set of targets is a family of membrane proteins. Successful production of specific affinity reagents to the ectodomains will showcase the potential of MegaSTAR to generate reagents to challenging targets.
NIH STTR award
More News and Events
-
Event
AACR Annual Meeting
Chicago, IL | April 25-30, 2025 Attending the 2025 AACR Annual Meeting? Schedule a meeting with Tango Biosciences experts to talk about your upcoming needs in antibody and affinity reagent discovery! The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and […]
-
News
Michael Scholle Appointed CEO of Tango Biosciences
Co-founder Brian Kay to assume Chief Scientific Officer, focused on scientific innovation and operations CHICAGO–Tango Biosciences, Inc., the premier research partner for custom affinity reagents by phage display, announced Michael Scholle, MS, MBA as Chief Executive Officer effective immediately. Scholle is one of three co-founders of Tango Biosciences and an active board member. This transition enables president […]
-
Event
SLAS 2025
Visit Tango Biosciences at the 2025 SLAS International Conference & Exhibition! January 25-29, 2025 | San Diego, CA Booth #2317 Plus, mark your calendar to join our Solution Spotlight presentation or join us for one of two poster presentations: Solution Spotlight: Rapid Phage Display Solutions ideal for SLAS: Screening Ligands for Affinity and Selectivity Tuesday, […]